Advanced

A review of pioglitazone HCL and glimepiride in the treatment of type 2 diabetes.

Dorkhan, Mozhgan LU and Frid, Anders LU (2007) In Vascular Health and Risk Management 3(5). p.721-731
Abstract
Type 2 diabetes (T2D) is a progressive disorder with a consistent and steady increase in glycosylated hemoglobin (HbA1c) over time associated with enhanced risk of micro- and macrovascular complications and a substantial reduction in life expectancy. There are three major pathophysiologic abnormalities associated with T2D: impaired insulin secretion, excessive hepatic glucose output, and insulin resistance in skeletal muscle, liver, and adipose tissue. These defects have been treated in clinical praxis by use of oral insulin secretagogues (sulfonylureas/ glinides) or insulin, biguanides, and thiazolidinediones (TZDs) respectively. Pioglitazone HCL is an insulin sensitizer in the TZD family and glimepiride is an insulin secretagogue in the... (More)
Type 2 diabetes (T2D) is a progressive disorder with a consistent and steady increase in glycosylated hemoglobin (HbA1c) over time associated with enhanced risk of micro- and macrovascular complications and a substantial reduction in life expectancy. There are three major pathophysiologic abnormalities associated with T2D: impaired insulin secretion, excessive hepatic glucose output, and insulin resistance in skeletal muscle, liver, and adipose tissue. These defects have been treated in clinical praxis by use of oral insulin secretagogues (sulfonylureas/ glinides) or insulin, biguanides, and thiazolidinediones (TZDs) respectively. Pioglitazone HCL is an insulin sensitizer in the TZD family and glimepiride is an insulin secretagogue in the SU family. This article reviews mechanisms of action and clinical data behind the use of these two commonly used oral hypoglycemic agents with documented efficacy and good safety profile of once-daily administration, alone or in combination with insulin or metformin, in the management of T2D in terms of glycemic and non-glycemic effects, tolerability and side effects, and impact on vascular health. (Less)
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
Sulfonylurea Compounds: therapeutic use, Thiazolidinediones: therapeutic use, Diabetes Mellitus, Sulfonylurea Compounds: adverse effects, Type 2: drug therapy, Type 2: blood, Blood Glucose: metabolism, Thiazolidinediones: adverse effects
in
Vascular Health and Risk Management
volume
3
issue
5
pages
721 - 731
publisher
Dove Press
external identifiers
  • pmid:18078023
  • scopus:36148960037
ISSN
1178-2048
language
English
LU publication?
yes
id
94a58947-6dc1-4842-8462-35148a04db24 (old id 1035310)
alternative location
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2291316
date added to LUP
2008-02-29 13:07:54
date last changed
2017-01-01 04:46:50
@article{94a58947-6dc1-4842-8462-35148a04db24,
  abstract     = {Type 2 diabetes (T2D) is a progressive disorder with a consistent and steady increase in glycosylated hemoglobin (HbA1c) over time associated with enhanced risk of micro- and macrovascular complications and a substantial reduction in life expectancy. There are three major pathophysiologic abnormalities associated with T2D: impaired insulin secretion, excessive hepatic glucose output, and insulin resistance in skeletal muscle, liver, and adipose tissue. These defects have been treated in clinical praxis by use of oral insulin secretagogues (sulfonylureas/ glinides) or insulin, biguanides, and thiazolidinediones (TZDs) respectively. Pioglitazone HCL is an insulin sensitizer in the TZD family and glimepiride is an insulin secretagogue in the SU family. This article reviews mechanisms of action and clinical data behind the use of these two commonly used oral hypoglycemic agents with documented efficacy and good safety profile of once-daily administration, alone or in combination with insulin or metformin, in the management of T2D in terms of glycemic and non-glycemic effects, tolerability and side effects, and impact on vascular health.},
  author       = {Dorkhan, Mozhgan and Frid, Anders},
  issn         = {1178-2048},
  keyword      = {Sulfonylurea Compounds: therapeutic use,Thiazolidinediones: therapeutic use,Diabetes Mellitus,Sulfonylurea Compounds: adverse effects,Type 2: drug therapy,Type 2: blood,Blood Glucose: metabolism,Thiazolidinediones: adverse effects},
  language     = {eng},
  number       = {5},
  pages        = {721--731},
  publisher    = {Dove Press},
  series       = {Vascular Health and Risk Management},
  title        = {A review of pioglitazone HCL and glimepiride in the treatment of type 2 diabetes.},
  volume       = {3},
  year         = {2007},
}